title: HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.
authors.affiliation: The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA. jaellerh@mail.mdanderson.com
authors.forename: J A
authors.initials: JA
authors.lastname: Ellerhorst
authors.forename: W H
authors.initials: WH
authors.lastname: Hildebrand
authors.forename: J W
authors.initials: JW
authors.lastname: Cavett
authors.forename: M A
authors.initials: MA
authors.lastname: Fernandez-Vina
authors.forename: S
authors.initials: S
authors.lastname: Hodges
authors.forename: N
authors.initials: N
authors.lastname: Poindexter
authors.forename: H
authors.initials: H
authors.lastname: Fischer
authors.forename: E A
authors.initials: EA
authors.lastname: Grimm
mesh_terms: D000483:Alleles; D000951:Antigens, Neoplasm / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000401:mortality; D016207:Cytokines / Q000627:therapeutic use; D018572:Disease-Free Survival; D005787:Gene Frequency / Q000235:genetics; D006580:Genetic Carrier Screening; D005838:Genotype; D006239:Haplotypes; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006650:Histocompatibility Testing; D006720:Homozygote; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000401:mortality*; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000276:immunology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D016207:Cytokines; D000949:Histocompatibility Antigens Class II